US Patent 7,795,316: Claim Scope, Tobradex ST Coverage, Expiry Risk and Patent Landscape

US Patent 7,795,316 covers a viscous topical ophthalmic combination of tobramycin and dexamethasone formulated with deacetylated xanthan gum, an ionizable species, controlled ionic strength, acidic pH and defined viscosity characteristics. The commercial formulation most closely associated with the patent is Alcon’s TOBRADEX ST ophthalmic suspension.

The patent’s commercial value rests on the formulation architecture, not on the active ingredients alone. A competing product must avoid at least one required limitation of each asserted claim, such as the xanthan gum concentration, sodium-chloride-equivalent ionic concentration, pH, viscosity or in vitro/in vivo viscosity ratio.

What drug and formulation does US 7,795,316 protect?

The patent protects an ophthalmic suspension containing:

Limitation	Claimed range or requirement
Tobramycin	0.1 to 0.5% w/v
Dexamethasone	0.03 to 0.1% w/v
Deacetylated xanthan gum	0.3 to 0.9%
Ionic concentration	134 to 150 mM sodium chloride equivalent
In vitro viscosity	10 to 300 cP
Viscosity test shear rate	6 sec^-1
Viscosity test temperature	25°C
pH	5 to 6
In vitro/in vivo viscosity ratio	0.01 to 0.65 for claims containing that limitation
Preferred ionizable species	Sodium chloride, sodium sulfate or both

The narrower commercial embodiment recited in claims 10, 13, 16 and 19 contains:

0.3% w/v tobramycin;
0.05% w/v dexamethasone;
0.6% w/v xanthan gum;
sodium chloride, sodium sulfate or both; and
approximately pH 5.7.

These parameters correspond closely to the formulation disclosed for TOBRADEX ST, which FDA describes as a sterile topical ophthalmic suspension containing tobramycin 0.3% and dexamethasone 0.05% in a xanthan-gum-based vehicle [2].

How do the independent claims define infringement risk?

Claims 1, 12, 14 and 17 are the principal independent claims.

Claim 1: composition claim

Claim 1 requires every one of the following:

A topical ophthalmic composition.
Tobramycin within 0.1 to 0.5% w/v.
Dexamethasone within 0.03 to 0.1% w/v.
An aqueous ophthalmically acceptable vehicle.
Deacetylated xanthan gum at 0.3 to 0.9%.
An ionizable species that limits ionic interactions between tobramycin and the xanthan gum.
A sodium-chloride-equivalent ionic concentration of 134 to 150 mM.
In vitro viscosity of 10 to 300 cP at 6 sec^-1 and 25°C.
pH of 5 to 6.

A product outside any one numerical range may avoid literal infringement of claim 1. The most commercially practical design-around routes are to use a different polymer, alter the ionic strength outside the claimed range, use a pH below 5 or above 6, or produce a viscosity outside 10 to 300 cP under the specified test conditions.

Those routes require formulation-development validation. A formulation can remain within the claim despite changes to inactive-ingredient identity if the resulting ionic concentration, pH and viscosity remain within the claimed parameters.

Claims 12 and 13: method-of-treatment claims

Claims 12 and 13 cover topical application to an affected eye for an inflammatory ophthalmic condition where infection or risk of infection exists.

Claim 12 incorporates the broad composition of claim 1. Claim 13 incorporates the narrower formulation of claim 10. These claims create potential method liability for a manufacturer that labels a product for the claimed therapeutic use, even if the product is sold through an ANDA rather than directly marketed as TOBRADEX ST.

The method claims are narrower than a general combination-product claim because they require the specified ophthalmic use. Label language, prescribing information and physician-directed use are relevant to induced-infringement analysis under 35 U.S.C. §271(b).

Claims 14 and 17: independent composition claims with additional limitations

Claim 14 repeats the claim 1 composition but adds the in vitro/in vivo viscosity ratio of 0.01 to 0.65.

Claim 17 combines:

the active-ingredient ranges;
deacetylated xanthan gum;
the ionic concentration;
pH 5 to 6;
the listed ionizable species; and
the in vitro/in vivo viscosity ratio.

These claims are narrower than claim 1 but may be more commercially significant if the marketed product’s measured ocular residence and laboratory viscosity satisfy the ratio.

What formulations are protected by the dependent claims?

The dependent claims create a nested set of formulation positions.

Claim group	Added limitation	Commercial significance
2 and 7	Inorganic electrolytes, organic buffers or both	Broad functional category
3 and 8	Enumerated salts and buffer systems	Captures common ophthalmic excipients
4 and 9	Sodium chloride, sodium sulfate or both	More closely aligned with commercial formulation
5	Initial viscosity of 25 to 175 cP	Narrows the rheological profile
6	In vitro/in vivo viscosity ratio of 0.01 to 0.65	Adds ocular-performance limitation
10, 13, 16 and 19	0.3% tobramycin, 0.6% xanthan gum, 0.05% dexamethasone	Targets the commercial-strength formulation
11	pH about 5.7	Narrows the preferred pH
14, 17 and related claims	Combination of viscosity-ratio and composition limitations	Provides fallback positions

The patent does not require every excipient used in TOBRADEX ST. Preservatives, chelating agents, surfactants and pH adjusters are not generally recited in the principal claims. That omission broadens the claim’s potential reach across formulations using materially different inactive-ingredient packages.

How strong is the patent estate for the formulation?

The patent is technically focused but commercially targeted. Its strength varies by limitation.

Strong claim elements

The strongest limitations are the combination of:

deacetylated xanthan gum;
tobramycin and dexamethasone at the claimed concentrations;
sodium-chloride-equivalent ionic concentration of 134 to 150 mM;
pH 5 to 6; and
viscosity measured under a specified shear rate and temperature.

This combination is more difficult to avoid accidentally than a simple active-ingredient claim. A generic developer must control both composition and performance during development and must preserve documentation demonstrating the selected design-around.

Vulnerable claim elements

The following elements may create validity or enforcement issues:

Functional language. The phrase “in an amount sufficient to limit ionic interactions” may raise definiteness and enablement questions if the specification does not provide a reproducible test for determining when ionic interactions are sufficiently limited.
Viscosity ratio. The in vitro/in vivo viscosity ratio is potentially difficult to measure consistently. The claim does not, on its face, define the exact in vivo measurement protocol, patient population, sampling time or calculation method.
Deacetylated xanthan gum terminology. The claims alternate between “deacetylated xanthan gum” and “xanthan gum.” Claim construction may determine whether ordinary xanthan gum falls within the claims or whether the claims require a specifically deacetylated material.
Numerical endpoints. The ranges use precise endpoints. A formulation at 133 mM or 151 mM may present a literal-infringement distinction, although measurement error, rounding and the doctrine of equivalents can affect the analysis.
Claim 17 drafting issue. The phrase “0.1 to 0.5 w/v tobramycin” omits the percent symbol appearing in the other claims. The omission creates a drafting ambiguity, although the specification, prosecution history and dependent claims would likely be used to interpret the intended concentration range.

What is the Orange Book status of US 7,795,316?

TOBRADEX ST is an FDA-approved ophthalmic suspension marketed by Alcon. Its regulatory basis is NDA 021320, and the FDA-approved product contains tobramycin and dexamethasone for steroid-responsive ocular inflammation where bacterial infection or risk of infection exists [2].

The patent is relevant to the Orange Book analysis because the claims cover the commercial formulation rather than merely the active ingredients. Orange Book-listed patents can affect an ANDA applicant’s certification and the timing of approval under the Hatch-Waxman framework [3, 4].

The practical Orange Book questions are:

whether US 7,795,316 is currently listed against the relevant TOBRADEX ST NDA;
whether the patent’s statutory term has expired;
whether any later continuation or related patent remains listed;
whether an ANDA applicant filed a Paragraph IV certification; and
whether FDA approval is subject to a 30-month stay from patent litigation.

The patent number and claim text alone do not establish the current Orange Book listing or live enforceability status. The controlling sources are the FDA Orange Book entry, USPTO Patent Center, the patent’s maintenance-fee record and any terminal-disclaimer or patent-term-adjustment data.

When does US 7,795,316 lose exclusivity?

The patent’s enforceable term depends on the earliest effective nonprovisional filing date, any applicable patent-term adjustment, terminal disclaimer and maintenance-fee status. Patent expiration cannot be calculated reliably from the grant date of September 14, 2010.

The relevant legal rule is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. §§154 and 156 [5]. FDA regulatory exclusivity is separate from patent exclusivity.

Exclusivity category	Relevance
Patent exclusivity	Determined by the USPTO term calculation
New-drug exclusivity	Determined by the NDA approval and applicable FDA exclusivity category
Three-year formulation exclusivity	Potentially relevant to the approved new formulation
Pediatric exclusivity	Applies only if FDA granted the statutory extension
Orphan exclusivity	Not generally associated with this product
Biosimilar exclusivity	Not applicable because TOBRADEX ST is a small-molecule ophthalmic product

The product does not present a biosimilar pathway issue. A competing manufacturer would generally pursue an ANDA or, depending on the formulation and regulatory strategy, a 505(b)(2) application. The principal regulatory risk is therefore generic or follow-on ophthalmic competition, not biosimilar substitution.

Which companies are challenging the patent?

The supplied claim text identifies no Paragraph IV certification, ANDA filer or litigation defendant. A reliable challenge assessment requires current FDA Orange Book records and federal court dockets.

For this product class, a Paragraph IV challenger would typically attack the patent through one or more of the following positions:

noninfringement based on a polymer other than deacetylated xanthan gum;
ionic strength outside 134 to 150 mM;
pH outside 5 to 6;
viscosity outside the claimed range;
failure to satisfy the in vitro/in vivo viscosity ratio;
indefiniteness of “limit ionic interactions”;
lack of written description for the full numerical combinations;
obviousness over prior ophthalmic tobramycin/dexamethasone suspensions and xanthan-gum vehicles; or
lack of enablement across the full combination of concentration, ionic strength, pH and rheology ranges.

The most credible validity attack would likely combine prior art on tobramycin/dexamethasone ophthalmic products with prior art on xanthan-gum viscosity control and isotonic ophthalmic vehicles. The patent’s defense would focus on the interaction between cationic tobramycin, deacetylated xanthan gum, electrolyte concentration and ocular residence.

What generic launch scenarios exist?

Scenario 1: same-strength xanthan-gum formulation

A product using 0.3% tobramycin, 0.05% dexamethasone and approximately 0.6% deacetylated xanthan gum would face the highest infringement risk if its pH, ionic strength and viscosity also fall within the claimed ranges.

Scenario 2: alternative polymer

Replacing deacetylated xanthan gum with a different viscosity-enhancing polymer may avoid literal infringement. The developer must assess whether the substitute is chemically or functionally equivalent and whether other patents protect the alternative polymer system.

Scenario 3: altered ionic strength

Moving outside the 134 to 150 mM sodium-chloride-equivalent range may provide a straightforward design-around. The commercial tradeoff is potential impact on tonicity, comfort, stability, viscosity and ocular residence.

Scenario 4: altered pH

A formulation with pH below 5 or above 6 may avoid the principal claims. This approach is constrained by dexamethasone stability, tobramycin stability, ocular tolerability and preservative performance.

Scenario 5: different regulatory product

A 505(b)(2) applicant could develop a materially different ophthalmic suspension or solution. Patent exposure would depend on the final formulation and labeling, while regulatory bridging and clinical requirements could increase development cost and timing.

How does US 7,795,316 compare with ordinary TOBRADEX patents?

The patent is formulation-specific.

Patent type	Typical protected subject matter	Relevance to US 7,795,316
Active-ingredient patent	Tobramycin, dexamethasone or combination use	Usually expired or not the principal barrier
Method-of-use patent	Treating ocular inflammation or infection risk	Claims 12 and 13 address this category
Formulation patent	Xanthan-gum vehicle, ionic strength and viscosity	Core subject of US 7,795,316
Manufacturing patent	Mixing order, sterilization, suspension processing	Not expressly covered by the supplied claims
Device patent	Dropper, container or delivery system	Not covered by the supplied claims
Regulatory exclusivity	FDA approval-based delay	Separate from patent rights

The patent does not claim a manufacturing process, container, dropper or packaging configuration. A competitor could therefore encounter a lower formulation-development barrier than a patent estate that combines composition, process and device claims.

What geographic coverage does the patent provide?

US 7,795,316 provides rights only in the United States. It does not directly block sales in Canada, Europe, Japan, China or other markets.

International protection would depend on related national filings from the same priority family. Separate foreign patents must be reviewed for:

claim scope;
legal status;
expiration date;
supplementary protection or patent-term extensions;
opposition or revocation proceedings; and
local regulatory linkage.

A US freedom-to-operate conclusion cannot be extended to foreign markets without a jurisdiction-specific review.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barrier is reproducible control of the rheological profile. The formulation must maintain:

uniform xanthan-gum hydration;
acceptable particle suspension;
consistent ionic strength;
pH stability;
preservative effectiveness;
sterility or aseptic quality;
drop-size performance; and
acceptable ocular comfort.

A generic developer may avoid US 7,795,316 while still facing separate risks involving process know-how, trade secrets, excipient grades, analytical methods, regulatory equivalence and other Alcon patents.

Key Takeaways

US 7,795,316 is a formulation patent directed to tobramycin/dexamethasone ophthalmic suspensions using deacetylated xanthan gum.
The principal claim limitations are 0.1 to 0.5% tobramycin, 0.03 to 0.1% dexamethasone, 0.3 to 0.9% xanthan gum, 134 to 150 mM sodium-chloride-equivalent ionic strength, pH 5 to 6 and controlled viscosity.
Claims 10, 13, 16 and 19 target the commercial-strength formulation associated with TOBRADEX ST.
The patent does not require every inactive ingredient in the marketed product, which broadens potential formulation coverage.
The in vitro/in vivo viscosity ratio and “limit ionic interactions” language are important potential validity and claim-construction pressure points.
The product is a small-molecule ophthalmic product. Biosimilar competition is not relevant.
Generic competition would most likely use a polymer, pH, ionic strength or viscosity design-around, or challenge the claims through Paragraph IV.
Current Orange Book listing, patent expiration, maintenance-fee status and Paragraph IV litigation must be determined from FDA, USPTO and court records rather than the claim text alone.

FAQs About US Patent 7,795,316

Does US 7,795,316 cover generic tobramycin/dexamethasone suspension?

Only if the generic product satisfies all required limitations of an asserted claim. A generic containing the two active ingredients but using a different polymer or falling outside the claimed ionic-strength, pH or viscosity ranges may avoid literal infringement.

Is TOBRADEX ST protected by a patent or FDA exclusivity?

TOBRADEX ST may be affected by both patent rights and FDA regulatory exclusivity. The duration and current status of each must be assessed separately because FDA exclusivity does not extend the patent term.

Can a competitor use sodium chloride instead of sodium sulfate?

Sodium chloride is expressly listed in the claims. Use of sodium chloride does not avoid the patent if the other claim limitations are met.

Does the patent cover an ophthalmic solution without xanthan gum?

The supplied claims require deacetylated xanthan gum. A solution without that polymer would have a strong noninfringement position against these claims, although other patents could apply.

Is a 505(b)(2) application automatically free of this patent?

No. A 505(b)(2) applicant remains exposed if its product or labeling falls within an enforceable composition or method claim. The regulatory pathway does not eliminate patent infringement risk.

References

United States Patent No. 7,795,316. (2010). Ophthalmic compositions containing tobramycin and dexamethasone. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). TOBRADEX ST (tobramycin and dexamethasone ophthalmic suspension) prescribing information. Alcon Laboratories, Inc.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §355(j).
Patent Act, 35 U.S.C. §§154, 156, 271.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	TOBRADEX ST	dexamethasone; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050818-001	Feb 13, 2009		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 7,795,316

Which drugs does patent 7,795,316 protect, and when does it expire?

Summary for Patent: 7,795,316